Introduction {#Sec1}
============

Since the 1980s, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) have been spreading worldwide \[[@CR1], [@CR2]\]. Several reports underline the concomitant increasing use of carbapenems \[[@CR3], [@CR4]\]. Indeed, the recently published 2015 ESAC report noted a threefold increased use of carbapenems between 2010 and 2014 \[[@CR5]\]. This induces a selective pressure for carbapenem-resistant isolates, and recent data suggest that even a brief exposure to carbapenems increases the risk of colonization with carbapenem-resistant bacteria (CRB) in intensive care unit patients \[[@CR6]\].

To reduce the ecological risk associated with the increased consumption of last-line antibiotics, two main strategies are available: (1) searching for alternative treatments for ESBL-PE-related infections and (2) antimicrobial de-escalation (ADE). Therefore, the use of alternatives to carbapenems such as cephamycins, piperacillin--tazobactam and others for the treatment of ESBL-PE infections should be investigated. A recent systematic review, including two randomized controlled trials and 12 cohort studies, highlighted that the effects of ADE on antimicrobial resistance have not been properly studied \[[@CR7]\]. However, this strategy is largely promoted by several scientific societies and specifically in critically ill patients \[[@CR8], [@CR9]\]. Indeed, for severely ill patients, international guidelines recommend the use of broad-spectrum antibiotics as first-line therapy to minimize the risk of inadequate initial antimicrobial treatment, and suggest streamlining initial antibiotic therapy and narrowing the spectrum whenever possible once the pathogen(s) are identified \[[@CR10]\].

Until recently, the common rule is to treat infections caused by ESBL-producing organism with carbapenems. However, ESBLs are inhibited in vitro by beta-lactamase inhibitors and several studies have suggested the use of β-lactam/β-lactamase inhibitor combinations (BL/BLIs) such as piperacillin--tazobactam as a carbapenem-sparing strategy for the treatment of ESBL-PE-related infections \[[@CR11]--[@CR13]\]. The recent EUCAST and CLSI \[[@CR14], [@CR15]\] guidelines include BL/BLIs and other beta-lactams (cefepime, third generation cephalosporins, temocillin, cefoxitin) as treatment options for infections caused by ESBL-producing organisms. For a long time, AST categorization was based not only on MIC and zone diameter measurements but also on the detection of individual resistance mechanisms, i.e., interpretative reading. Even if in vitro results indicated susceptibility to a drug, the reported category was edited to "resistant" if the presence of a resistance mechanism was confirmed, e.g., in the case of extended-spectrum beta-lactamases (ESBLs). To limit the consumption of carbapenems, CLSI and EUCAST recently abandoned editing of AST reports based on the detection of ESBLs.

While several studies are conducted in ICU, data remain scarce concerning other beta-lactams in non-ICU- \[[@CR16], [@CR17]\] and ICU-infected \[[@CR18]--[@CR21]\] patients. Therefore, only BL/BLIs such as piperacillin--tazobactam (Pip--Taz) could be used in ICU patients, but there are concerns that: (1) no randomized controlled trials compared specifically carbapenems to Pip--Taz for the treatment of ESBL-PE-related infections \[[@CR22]\]; (2) in vitro susceptibility to β-lactamase inhibitors might not predict clinical efficacy; and (3) the success of BL/BLIs depends on pharmacokinetic--pharmacodynamic target attainment, which current dosing recommendations may not guarantee. Therefore, alternatives are seldom used in clinical practice for treating serious infections caused by ESBL-PE.

In critically ill patients, pharmacokinetics of beta-lactam antibiotics differs from healthy volunteers. Lower than expected concentrations have been reported for meropenem, piperacillin, amoxicillin, as well as for cephalosporins \[[@CR23]--[@CR26]\]. Besides, the risk of treatment failure may be exacerbated when using antibiotics exposed to the inoculum effect \[[@CR27]\], as are most beta-lactams.

This narrative review, based on microbiological, pharmacodynamics, clinical and ecological data, describes the available evidence for the use of Pip--Taz as an alternative to carbapenems in critically ill patients and to provide some guidance to prescribers for using these drugs when treating infections caused by ESBL-PE.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

A literature search was performed via PubMed, including all records from 1990 through April 2016. The following search pattern was applied: (ESBL OR extended-spectrum β-lactamases) AND (infection) AND (cefepime OR cefoxitine OR cephamycins OR flomoxef OR BL/BLI OR Piperacillin--tazobactam OR Carbapenems OR temocillin OR alternatives). Reference lists were cross-checked to identify further publications for possible inclusion. We restricted inclusion to studies published in the English, Spanish and French languages.

Selection criteria {#Sec4}
------------------

We screened and included studies in three categories according to the following criteria: (1) pharmacokinetics and pharmacodynamics studies, where all studies investigating the PK/PD of the potential alternatives to carbapenems in ICU patients were included. (2) For clinical studies, we restricted inclusion to studies reporting mortality of patients receiving empirical or definitive treatment with a non-carbapenem therapy for an ESBL bacteremia in adult patients. Patients with community-, hospital- and healthcare-associated bacteremia were eligible for inclusion. (3) Finally, considering ecological studies, we included any published article reporting carbapenem-resistant Enterobacteriaceae (CRE). Among the eligible articles, studies were included if they reported on exposure to any previous antibiotic class as a risk factor associated with CRE acquisition.

Results {#Sec5}
=======

Microbiological susceptibility {#Sec6}
------------------------------

Several studies suggested that ESBL-PE were susceptible to non-carbapenem beta-lactams. However, the prevalence of susceptibility depends on the species concerned, the antibiotic class and local epidemiology. ESBL-producing *E. coli* is usually regarded as more susceptible to all beta-lactams than ESBL-producing *K. pneumoniae*, piperacillin--tazobactam (Pip--Taz) being the most effective antibiotic \[[@CR28]\]. North American data from the 2010--2014 SMART programs find that 4, 10 and 46% of ESBL-producing *E. coli* were susceptible to ceftriaxone, cefepime and ceftazidime, respectively \[[@CR28]\], whereas 96--98 and 69% of ESBL-producing *E. coli* isolates from urinary tract \[[@CR29]\] and from patients with pneumonia \[[@CR30]\] were found susceptible in vitro to Pip--Taz, respectively. Conversely, only 26.9% of ESBL-producing *Klebsiella* spp. isolates from patients with pneumonia were susceptible to Pip--Taz \[[@CR30]\]. Asian data on ESBL-producing *E. coli* find similar susceptibilities, with 1.6, 9.5, 33.4 and 84.5% isolates susceptible to cefotaxime, cefepime, ceftazidime and Pip--Taz, respectively \[[@CR29]\]. It is noteworthy that in silico PK/PD studies aiming to evaluate the use of alternatives to carbapenems for treatment of ESBL-PE infections suggest that ESBL-Kp susceptibility is overestimated by conventional methods in comparison with E-test susceptibility testing.

Pharmacokinetics and pharmacodynamics studies {#Sec7}
---------------------------------------------

According to epidemiological data, two main antibiotics could be used as an alternative to carbapenems: piperacillin and cefoxitin. Others antibiotics suggested in the literature as temocillin, ceftolozane/tazobactam and/or ceftazidime/avibactam are less tested. Our goal was to define the optimal condition for using these antibiotics for ESBL-PE-related infections in ICU.

The pharmacokinetics of piperacillin in ICU patients was quite extensively investigated. There is, however, a lack of consensus on the pharmacokinetic/pharmacodynamic target to be achieved. Indeed targets as different as obtaining a free concentration \> MIC (fT \> MIC) or \> 4 times the MIC (fT \> 4xMIC) for 50 or 100% of a dose interval have been considered \[[@CR31]--[@CR36]\]. This is a crucial point as the dose to be administered will vary considerably according to the chosen target. There are, however, increasing data supporting a minimal efficacy criteria of fT \> MIC = 100% in ICU patients, while a total trough concentration/MIC ratio of at least three was found to prevent the emergence of resistance in vitro \[[@CR37]--[@CR40]\]. Therefore, based on these more drastic PK/PD endpoints, it seems a dose of 4.5 g TID given as intermittent infusions should not be considered any more in ICU patients with normal renal functions \[[@CR32], [@CR36]\]. A 4.5-g × 4 daily dose appears more convenient, provided it is administered as prolonged infusion of at least 3 h \[[@CR32], [@CR34]\]. Indeed, for an intermittent bolus administration, a 4gx4 dose is associated with a very low probability of target attainment, even for the lowest PK/PD target of T \> MIC = 50% \[[@CR32]\]. However, even with a 4.5-g x 4 dose given by extended 3-h infusions, around one-third of the patients may not achieve a fT \> MIC = 100%, which supports the need for an individual dose adjustment using therapeutic drug monitoring \[[@CR35]\]. Such a result strongly supports the use of continuous infusion, and since this administration mode provides a better outcome than intermittent infusion \[[@CR24]\], we believe a 16-g daily dose given as a continuous infusion, following a 4.5-g loading dose, should be considered as a starting point in ICU patients with normal renal function. Such an approach was found relevant for the treatment of ventilator-associated pneumonia, as it allowed the achievement of alveolar concentrations \> 16 mg/L (i.e., the clinical breakpoint for gram-negative bacteria).

Slightly different results were observed in morbidly obese ICU patients, for whom the elimination half-life of piperacillin seems to be increased, compared to non-obese patients, resulting in an increased fT \> MIC for equivalent doses \[[@CR33]\]. Consequently, a 4.5-g × 4 daily dose given as a 4-h extended infusion should provide satisfying trough concentrations \[[@CR33]\].

The pharmacokinetics of piperacillin in ICU patients undergoing continuous renal replacement therapy (CRRT) was also investigated, and similar results were found in case of venovenous hemofiltration or hemodiafiltration. A 4.5-g TID dose given as 30-min infusion should provide a free concentration \> MIC for the entire dosing interval in almost all patients. Extending the infusion duration to 4 h should allow the attainment of several times the MIC. However, dose requirements seem to importantly depend on the membrane used and the effluent rate that are major aspects of CRRT poorly investigated to date \[[@CR41], [@CR42]\]. An interesting point is that piperacillin concentration in the dialysate effluent is equal to the free plasma concentration and can therefore be used for the individual adaptation of the dose via therapeutic drug monitoring (TDM) \[[@CR43]\]. To our knowledge, the PK of piperacillin in the context of intermittent hemodialysis was not investigated to date in ICU patients. Based on the results obtained in sepsis-free volunteers with chronic renal failure \[[@CR44]\], a dose of 4.5 g bid could be used as a starting point, with a subsequent TDM-guided individual adjustment of the dose. Conflicting results are available about the percentage of the dose that is eliminated by a 4-h session of hemodialysis (i.e., from 10 to 50%) \[[@CR45], [@CR46]\]. However, because a supplemental elimination is likely to occur during hemodialysis, it seems preferable to administrate the drug just after the end of the hemodialysis session.

Cefoxitin PK in ICU patients was not investigated to date. By using the PK parameters obtained in healthy subjects, it was shown that for a 8-g daily dose of cefoxitin, only an administration by continuous infusion provided a high probability to achieve targets of fT \> MIC = 100% and fT \> 4 × MIC = 100% for ESBL-PE \[[@CR47]\]. However, since PK differences are expected in ICU subjects, PK data in this population are obviously needed \[[@CR48]\].

Concerning temocillin, a 2-g TID dose given as intermittent 30-min infusion, provides a high probability to attain fT \> MIC = 100% in ICU patients with normal renal function, provided the MIC is ≤ 4 mg/L. For higher MIC, administration of the same daily dose by continuous infusion is preferable \[[@CR49]\]. In summary, among the different antibiotics suggested as alternatives to carbapenems, Pip--Tz is the one with the most frequent published PK/PD data in ICU. High daily doses and prolonged infusion should be promoted for ESBL-PE-related infections in ICU patients.

Clinical studies {#Sec8}
----------------

The article selection process is shown in Fig. [1](#Fig1){ref-type="fig"}. Of the 54 articles selected initially, 23 provided data among patients treated with BL/BLIs for ESBL-producing Enterobacteriaceae-related infections (Table [1](#Tab1){ref-type="table"}). Most of the published studies were retrospective (17/23; 73.9%), and all others were observational. Community-acquired, healthcare-associated and nosocomial infections were included without distinction. Among these 23 studies, 9 (39.1%), 6 (26%) and 7 (30.4%) evaluated antibiotic therapy as empirical therapy (ETC), definitive therapy or both, respectively. Among carbapenems, the selected molecule was available in 53% of included studies and imipenem--cilastatin was the most frequently used (45.7% of studies) followed by meropenem (35.2%) and ertapenem (19.1%).Fig. 1Flow diagram of the selection process of the included studies Table 1Studies characteristicsAuthor/year of publicationStudy design, regionNo. of patients, ESBL/totalType of infection (*n*, %)Bacteria (*n*, %)ICU (*n*,  %)ETC/DTCTreatment (*n*, %)MICAdministration (CI, PI or II)PosologyApisarnthanarak et al. \[[@CR52]\]SC case--control,\
2003--2007, Thailand36/146UK (36, 100%)*E. coli*\
*K. pneumoniae*UKETC (36, 100%)Cephalosporins (17, 47.2%)\
BL/BLI (10, 27.8%)\
Carbapenem (5, 13.9%)\
Fluoroquinolones (4, 11.1%)NUKUKBalakrishnan et al. \[[@CR94]\]MC retrospective cohort, 2008--2010, United Kingdom42/42UKUKUKDTC (42, 100%)Temocillin (42, 100%)YIIYBin et al. \[[@CR95]\]SC prospective cohort, 2002--2005, China22/22IIA (11, 50%)\
Primary bacteraemia (6, 27.2%)\
UTI (5, 22.7%)*E. coli* (22, 100%)UKDTC (22, 100%)Carbapenem (8, 36.4%)\
Cephalosporins (7, 31.8%)\
BL/BLI (7, 31.8%)YYUKChaubey et al. \[[@CR96]\]MC prospective cohort, 2000--2007, Canada79/79Primary bacteraemia (39, 49.3%)\
UTI (38, 48.1%)\
Pneumonia (2, 2.5%)\
IIA (1, 1.3%)*E. coli* (72, 91.1%)\
*K. pneumonia*e (7, 8.9%)UKETC (74, 93.7%)\
DTC (79, 100%)Carbapenem (16, 20.2%)\
BL/BLI (16, 20.2%)\
Aminoglycosides (16, 20.2%)\
Fluoroquinolones (16, 20.2%)\
Cephalosporins (16, 20.2%)\
Carbapenem (16, 20.2%)\
BL/BLI (16, 20.2%)\
Fluoroquinolones (16, 20.2%)\
Sulfamides (16, 20.2%)\
Aminoglycosides (16, 20.2%)NUKUKChopra et al. \[[@CR50]\]MC retrospective cohort, 2005--2007, USA145/145UK*E. coli* (24, 16.6%)\
*K. pneumoniae* (121, 83.4%)Y (37, 25,5%)ETC (128, 88.2%)\
DTC (110)Cephalosporins (85, 58.6%)\
Carbapenem (50, 34.4%)\
Fluoroquinolones (6, 3.9%)\
Aminoglycosides (4, 3.1%)\
Carbapenem (103, 70.9%)\
Cephalosporins (41, 28.2%)\
BL/BLI (24, 16.4%)\
Fluoroquinolones (17, 11.8%)\
Amikacin (17, 11.8%)\
Tigecycline (12, 8.2%)YUKUKChung et al. \[[@CR97]\]SC retrospective cohort, 2005--2010, Taiwan122/122UTI (47, 38.5%)\
Primary bacteraemia (21, 17.2%)\
IIA (22, 18%)\
Pneumonia (6, 4.9%)\
CVC (6, 4.9%)\
Skin and soft tissue (4, 3.3%)\
Surgical site infection (3, 2.5%)\
Other (13, 10.7%)*E. coli* (122, 100%)UKDTC (107 87.7%)Carbapenem (71, 57.9%)\
Non-BL/BLI (48, 39.3%)\
BL/BLI (3, 2.8%)NUKUKDe Rosa et al. \[[@CR98]\]SC retrospective cohort, 2000--2007, Italy128/128Primary bacteraemia (61, 47.6%)\
IIA (55, 43%)\
UTI (12, 9.4%)*E. coli* (80, 62.5%)\
*K. pneumoniae* (28, 21.9%)\
*P. mirabilis* (20, 15.6%)Y (8, 6.3%)ETC (97 75.8%)Carbapenem (101, 79.3%)\
BL/BLI (10, 8.2%)\
Fluoroquinolone (8, 6.2%)\
Trimethoprim/sulfamethoxazole (1, 1%)\
Aminoglycosides (8, 6.2%)NUKUKDu et al. \[[@CR16]\]SC retrospective cohort, 1997--1999, China23/85Primary bacteraemia (9, 39.1%)\
IIA (5, 21.7%)\
Pneumonia (4, 17.4%)\
UTI (2, 8.7%)\
CVC (2, 8.7%)\
Other (1, 4.4%)*E. coli* (16, 69.5%)\
*K. pneumoniae* (7, 30.5%)NDTC (23, 100%)Carbapenem (13, 56.5%)\
Cephalosporins (7, 30.4%)\
Fluoroquinolone (2, 8.7%)\
Aminoglycosides (1, 4.4%)NUKUKEndimiani et al. \[[@CR99]\]SC retrospective cohort, 1997--2004, Italy9/23Primary bacteraemia (5, 55.6%)\
UTI (4, 44.4%)*P. mirabilis* (9, 100%)UKETC (9, 100%)\
DTC (9, 100%)Cephalosporins (5, 55.6%)\
BL/BLI (4, 44.4%)\
Cephalosporins (4, 44.4%)\
BL/BLI (3, 33.3%)\
Carbapenem (2, 22.3%)YYUKFerrandez et al. \[[@CR100]\]Retrospective cohort, 2000--2006, Spain53/53UK*E. coli*\
*K. pneumoniae*UK--Carbapenem (30, 56.6%)\
BL/BLI (5, 9.4%)\
Fluoroquinolone (4, 7.5%)\
Cephalosporins (2, 3.8%)\
Other (12, 22.7%)YUKUKGudiol et al. \[[@CR101]\]SC prospective observational study, 2006--2008, Spain17/135Primary bacteraemia (9, 52.9%)\
IIA (6, 35.3%)\
UTI (1, 5.9%)\
Other (1, 5.9%)*E. coli* (17, 100%)Y (2, 12%)ETC (17, 100%)\
DTC (17, 100%)BL/BLI (6, 35.3%)\
Carbapenem (5, 29.4%)\
Cephalosporins (5, 29.4%)\
Monobactam (1, 5.9%)\
Carbapenem (14, 82.3%)\
BL/BLI (2, 11.8%)\
Fluoroquinolone (1, 5.9%)NUKUKGutiérez-Gutiérez et al. \[[@CR51]\]MC, retrospective cohort study, 2004--2013, International601/601UTI (272, 45.2%)\
Other (258, 42.9%)\
IIA (71, 11.8%)*E. coli* (439, 73%)\
*K. pneumoniae* (114, 19%)\
Other (48, 8%)Y (64, 10.7%)ETC (365, 60.7%)\
DTC (601, 100%)Carbapenem (195, 53.5%)\
BL/BLI (169, 46.5%)\
Carbapenem (509, 84.7%)\
BL/BLI (92, 15.3%)NYIIHarris et al. \[[@CR102]\]SC retrospective cohort study, 2012--2013, China92/92UTI (43, 46.7%)\
Primary bacteramia (39, 42.2%)\
IIA (10, 11.1%)*E. coli* (79, 85.9%)\
*K. pneumoniae* (13, 14.1%)Y (11, 12.1%)DTC (47, 51%)Carbapenem (23, 48.9%)\
BL/BLI (24, 51.1%)NYIIKang et al. \[[@CR17]\]SC retrospective cohort study, 1998--2002, South Korea133/133IIA (82, 61.6%)\
Primary bacteraemia (33, 24.8%)\
UTI (14, 10.5%)\
Pneumonia (4, 3.1%)*E. coli* (67, 50.4%)\
*K. pneumoniae* (66, 49.6%)NETC (133, 100%)\
DTC (133, 100%)Non cephalosporins (29, 21.8%)\
Cephalosporins (104, 78.2%)\
Non cephalosporins (101, 75.9%)\
Cephalosporins (32, 24.1%)YUKUKKang et al. \[[@CR69]\]MC retrospective cohorts, 2008--2010, South Korea114/114UK*E. coli* (78, 68.4%)\
*K. pneumonia* (36, 31.6%)UKETC (114 100%)Carbapenem (78, 68.4%)\
Piperacillin/tazobactam (36, 31.6%)NUKUKLee et al. \[[@CR53]\]SC retrospective cohort, 2004--2005, Taiwan27/27Pneumonia (15, 55.5%)\
IIA (5, 18.5%)\
UTI (3, 11.1%)\
Primary bacteraemia (3, 11.1%)\
Other (1, 3.8%)*K. pneumonia* (27, 100%)Y (13, 48.1%)DTC (27, 100%)Carbapenem (20, 74%)\
Flomoxef (7, 26%)YUKUKLee and *al.* \[[@CR21]\]SC retrospective cohort, 2001--2008, Taiwan121/206CVC (48, 39.6%)\
Primary bacteraemia (32, 26.4%)\
Pneumonia (12, 9.9%)\
SSTI (9, 7.4%)\
UTI (9, 7.4%)\
IIA (6, 4.9%)\
Other (5, 4.3%)*E. cloacae* (121, 100%)Y (78, 64.4%)ETC (114, 94.2%)\
DTC (114, 94.2%)Cephalosporins (59, 49.1%)\
Carbapenem (26, 21%)\
BL/BLI (14, 11.4%)\
Other beta-lactam (13, 10.5%)\
Fluoroquinolones (3, 2.6%)\
Other Antibiotics (6, 5.4%)\
Carbapenem (53, 46.5%)\
Cephalosporins (38, 33.3%)\
Fluoroquinolones (16, 14%)\
BL/BLI (3, 2.6%)\
Other β-lactam (3, 2.6%)\
Other antibiotic therapy (1, 1%)NUKUKLee et al. \[[@CR54]\]MC retrospective cohort, 2002--2007, Taiwan178/178Pneumonia (43, 24.1%)\
UTI (39, 21.9%)\
CVC (37, 20.8%)\
IIA (28, 15.7%)\
Primary bacteraemia (25, 14%)\
SSTI (11, 6.3%)NDUKDTC (178, 100%)Carbapenem (161, 90,4%)\
Cefepime (17, 9.6%)YYIILee et al. \[[@CR103]\]MC retrospective cohort, 2007--2012, Taiwan389/389UTI (88, 22.6%)\
CVC (86, 22.1%)\
Pneumonia (80, 20.5%)\
IIA (61, 15.7%)\
Primary bacteraemia (62, 16%)\
SSTI (12, 3.1%)*E. coli* (156, 40.1%)\
*K. pneumoniae* (233, 59.9%)UKDTC (389, 100%)Carbapenem (257, 66%)\
Flomoxef (132, 34%)YUKUKMatsumura et al. \[[@CR104]\]MC retrospective cohort, 2005--2014, Japan113/1440UTI (57, 50.4%)\
IIA (32, 28.3%)\
Primary bacteraemia (19, 16.8%)\
Other (5, 4.5%)*E. coli* (113, 100%)UKETC (71, 62.8%)\
DTC (113, 100%)Carbapenem (45, 63.7%)\
Cefmetazole/flomoxef (26, 36.6%)\
Carbapenem (54, 47.8%)\
Cefmetazole/flomoxef (59, 52.2%)YUKUKOfer-Friedman et al. \[[@CR20]\]MC retrospective cohort, 2008--2012, International79/79Pneumonia (27, 34.2%)\
SSTI (22, 27.8%)\
IIA (20, 25.3%)\
Primary bacteraemia (6, 7.6%)\
Undetermined (4, 5.1%)*E. coli* (42, 53.1%)\
*K. pneumoniae* (22, 27.8%)\
*P. mirabilis* (15, 19.1%)\> 50%ETC (33, 41.8%)\
DTC (79, 100%)Carbapenem (24, 72.7%)\
Piperacillin/tazobactam (9, 27.3%)\
Carbapenem (69, 87.3%)\
Piperacillin/tazobactam (10, 12.7%)YUKUKQureshi et al. \[[@CR105]\]MC retrospective cohort, 2005--2008, USA21/UKUK*E. cloacae* (21, 100%)UKETC (21, 100%)Cephalosporins (9, 42.8%)\
Carbapenem (8, 38%)\
BL/BLI (4, 19.2%)YUKUKPaterson et al. \[[@CR55]\]Post hoc analysis MC prospective cohort, 1996--1997, International85/455UK*K. pneumoniae* (85, 100%)UKETC (71, 83.5%)Monotherapy\
Carbapenem (27, 38%)\
Fluoroquinolones (11, 15.5%)\
Cephalosporins (5, 7%)\
BL/BLI (4, 5.6%)\
Aminoglycosides (2, 2.8%)\
Combination therapy (15, 21.1%)\
Sequential monotherapy (7, 10%)NUKUKPilmis et al. \[[@CR106]\]MC retrospective cohort, 2011, France13/13Primary bacteraemia (11, 84.6%)\
UTI (2, 15.4%)*E. coli* (5, 38.4%)\
*K. pneumoniae* (7, 53.8%)\
*E. cloacae* (1, 7.8%)UKETC (13, 100%)\
DTC (13, 100%)Carbapenem (12, 92.3%)\
Cefoxitin (1, 7.7%)\
Carbapenem (11, 84.6%)\
Cefoxitin (2, 15.4%)NUKUKRetamar et al. \[[@CR107]\]Post hoc analysis MC prospective cohort, 2001--2007, Spain39/39UTI (11, 28.2%)\
Other source (28, 71.8%)*E. coli* (39, 100%)UKETC (39, 100%)BL/BLI (39, 100%)YUKUKRodriguez-Bano et al. \[[@CR12]\]Post hoc analysis MC prospective cohorts, 2001--2007, Spain192/192UTI or IIA (121, 63%)\
Other sources (71, 37%)*E. coli* (192, 100%)Y (24, 12.6%)ETC (103, 53.6%)\
DTC (174, 90.6%)Carbapenem (31, 30%)\
BL/BLI (72, 70%)\
Carbapenem (120, 68.9%)\
BL/BLI (53, 31.1%)NUKUKTamma et al. \[[@CR19]\]MC, Prospective cohort, 2008--2015, USA213/331CVC (97, 45.5%)\
IIA (55, 25.8%)\
UTI (44, 20.6%)\
Pneumonia (17, 8.1%)*K. pneumoniae* (145, 68%)\
*E. coli* (66, 31%)\
*P. mirabilis* (2, 1%)Y (71, 33.3%)ETC (213, 100%)Carbapenem (110, 51.6%)\
BL/BLI (103, 48.4%)YUKUKTsai et al. \[[@CR108]\]MC retrospective cohort, 2005--2012, Taiwan47/47UTI (24, 51%)\
Pneumonia (9, 19.1%)\
SSTI (7, 14.9%)\
CVC (5, 10.6%)\
IIA (3, 6.4%)\
Primary bacteraemia (2, 4.3%)*P. mirabilis* (47, 100%)UKDTC (40, 85.1%)Carbapenem (21, 52.5%)\
BL/BLI (13, 32.5%)\
Other antibiotic therapy (6, 15%)YUKUKTumbarello et al. \[[@CR109]\]SC retrospective cohort, 1999--2004, Italy186/186Primary bacteraemia (86, 46.2%)\
UTI (53, 28.4%)\
IIA (24, 12.9%)\
SSTI (20, 10.7%)\
Pneumonia (6, 3.2%)\
CVC (5, 2.7%)*E. coli* (104, 55.9%)\
*K. pneumoniae* (58, 31.2%)\
*P. mirabilis* (24, 12.9%)UKETC (186 100%)\
DTC (171, 91.9%)BL/BLI (45, 24.2%)\
Fluoroquinolones (45, 24.2%)\
Cephalosporins (38, 20.9%)\
Carbapenems (29, 15.4%)\
Aminoglycosides (29, 15.4%)\
Carbapenems (61, 35.7%)\
BL/BLI (55, 32.2%)\
Aminoglycosides (30, 17.5%)\
Fluoroquinolones (25, 14.6%)YUKUKTuon et al. \[[@CR110]\]SC retrospective cohort, 2006--2009, Brazil28/58UK*E. cloacae* (28, 100%)UKDTC (25, 89.2%)Carbapenems (15, 60%)\
BL/BLI (4, 16%)\
Non-BL/BLI (6, 24%)NUKUKTuon et al. \[[@CR90]\]SC retrospective cohort, 2006--2009, Brazil63/104UK*K. pneumoniae* (63, 100%)UKDTC (62, 98.4%)Carbapenems (43, 69.3%)\
Non-BL/BLI (17, 27.4%)\
BL/BLI (2, 3.1%)NUKUKWang et al. \[[@CR95]\]MC, prospective cohort, 2006--2015, USA68/68CVC (30, 44.1%)\
UTI (21, 30.9%)\
IIA (15, 22.1%)\
Pneumonia (10, 14.7%)\
SSTI (2, 2.9%)*Klebsiella sp.* (42, 62%)\
*E. coli* (24, 34%)\
*P. mirabilis* (2, 3%)Y (20, 29%)ETC (68, 100%)Carbapenem (51, 75%)\
Cephalosporins (17, 25%)NUKUK*BL/BLI* beta-lactam/beta-lactamase inhibitor, *CVC* central venous catheter, *DTC* definitive therapy cohort, *ETC* empirical therapy cohort, *ICU* intensive care unit, *IIA* intra-abdominal infection, *MC* multicentric, *SC* single center, *SSTI* skin and soft tissue infection, *UK* unknown, *UTI* urinary tract infection

Only 3 (13%) studies reported the doses of antibiotics \[[@CR19], [@CR20], [@CR50]\] and none reported the modalities of antibiotic's administration. Indeed administered doses in patients without renal failure were variable; however, imipenem was used in most cases at an average dose of 0.5 g every 6 h, whereas 1 g every 8 h and 1 g every 24 h were used for meropenem and ertapenem, respectively. The two species most frequently involved were *E. coli* and *K. pneumoniae.* All patients included in these studies had bacteremia, and the two most frequent sites of infection were urinary tract and intra-abdominal infection. MIC was taken into account in adjusting antibiotic therapy in 11 (47.8%) of the 23 studies.

As mentioned above, 11 studies included between 6 and 131 ICU patients. In fact, some of the same patients were included in different cohorts \[[@CR12], [@CR51]\]. Only 4 studies \[[@CR52]--[@CR55]\] included patients with pneumonia caused by ESBL-PE, representing 8--50% of patients with ESBL-PE-related infections, indicating that less than 30 patients with ESBL-related pneumonia could be evaluated. Data regarding outcome for patients treated with carbapenems versus alternatives were available from 20 (86.9%) of the 23 studies including bacteremic patients. Surprisingly, potential confounding factors, such as severity of underlying diseases or of infection, were seldom reported.

Among studies including ICU patients, 6 (56%) compared BL/BLIs to carbapenems as empirical therapy. However, BL/BLIs was the only alternative compared to carbapenems in only 3 studies \[[@CR12], [@CR20], [@CR51]\]. In these studies, *E. coli* and *K. pneumoniae* represented more than two-third of the isolates and MICs were taken into account in only one study \[[@CR20]\]. The difference of mortality didn't reach statistical significance in two studies \[[@CR12], [@CR51]\]. However, Ofer-friedman et al. \[[@CR20]\] conducted a multicenter observational study including non-urinary BSI and comparing BL/BLI to carbapenem for the treatment of ESBL. In contrast to other studies, E*. coli* accounted for only half of the bloodstream infections; the median piperacillin MIC was 8 mg/L, and approximately half of patients required ICU care. In this study, the mortality was significantly higher in the piperacillin--tazobactam group \[OR 7.9 (1.2--53)\]. Thus, BL/BLIs may lead a poorer outcome than carbapenem therapy for critically ill patients with ESBL-PE infection from non-urinary sources.

Finally 7/11 (63%) studies compared BL/BLIs to carbapenems as definitive therapy, of which 4 (36.3%) compared BL/BLIs as the only alternative to carbapenems \[[@CR12], [@CR19], [@CR20], [@CR22], [@CR51]\]. It should be noted that only one of these studies took into account MICs \[[@CR20]\], whereas none took into account dosages and modalities of administration for assessing the effectiveness of therapy \[[@CR19]\].

Ecological studies {#Sec9}
------------------

While initial research suggested the relative safety of imipenem--cilastatin on the intestinal microbiota \[[@CR56]\], the recent analysis of rectal colonization of large number of ICU patients found that even a brief exposure to imipenem is a risk factor for carriage of resistant GNB in the intestinal flora \[[@CR6]\].

The effect of non-carbapenem antibiotics on the emergence of multidrug-resistant bacteria and specifically carbapenem resistance is a major issue. In animal models, imipenem--cilastatin had no effect on the indigenous microflora \[[@CR56]\]. In a mouse model, clindamycin and piperacillin--tazobactam promoted colonization, while ertapenem did not promote the establishment of intestinal colonization with KPC-Kp \[[@CR57]\]. Also several authors highlighted the risk associated with the emergence/selection of resistant strains when using Pip--Taz. Firstly, in vitro/in vivo studies \[[@CR27]\] suggested that Pip--Taz seems to be less resistant to the inoculum effect comparing to carbapenems. Secondly, several clinical studies \[[@CR58]\] underlined the risk of promoting vancomycin-resistant enterococci (VRE) colonization. Finally the emergence of carbapenem-resistant PE has been documented for a variety of antibiotics in the clinical setting \[[@CR59]\] (Table [2](#Tab2){ref-type="table"}): Fluoroquinolones \[[@CR60], [@CR61]\], extended-spectrum cephalosporin \[[@CR62]\], antipseudomonal penicillins \[[@CR63]\] and β-lactams/β-lactamase inhibitors \[[@CR64]\] have all been identified as risk factors for carbapenem resistance in *Klebsiella pneumoniae*.Table 2Studies addressing the risk related to previous antibiotic therapy and emergence of carbapenem-resistant EnterobacteriaceaeYearStudy designType of infectionAntibiotic concernedOR, 95 % CIWang \[[@CR62]\]2016Retrospective case--case--controlNosocomial infectionThird--fourth-generation cephalosporins\
Carbapenems4.557 (1.971--10.539)\
4.058 (1.753--9.397)Mittal G \[[@CR80]\]2016ProspectiveColonizationAminoglycosides4.14 (1.14--14.99)Ling \[[@CR81]\]2015Retrospective case--controlInfection or colonizationPenicillins\
Glycopeptides4.640 (1.529--14.079)\
5.162 (1.377--19.346)Jiao Y \[[@CR82]\]2015Retrospective case--controlInfection or colonizationGlycopeptides\
Cefoperazone plus sulbactam43.84 (1.73--1111.9)\
49.56, (1.42--1726.72)Candevir \[[@CR83]\]2015Retrospective cohortInfectionMeropenem\
Third-generation cephalosporins3.244 (1.193--8.819)\
3.590 (1.056--12.209)Gómez Rueda \[[@CR84]\]2014Retrospective case--case--controlInfectionCarbapenems3.3 (1.2--9.3)Ahn \[[@CR85]\]2014Retrospective case--controlColonization/infectionFluoroquinolones\
Carbapenems2.82 (1.14--6.99)\
4.56 (1.44--14.46)Mantzarlis \[[@CR86]\]2013Prospective cohortPneumoniaColistin\*1.156 per day (1.010--1.312)Dizbay \[[@CR87]\]2013Prospective cohortNosocomial infectionImipenem3.35 (1.675--6.726)Orsi \[[@CR88]\]2013Retrospective case controlBSICarbapenem7.74 (1.70--35.2)Chang \[[@CR89]\]2011Retrospective case--controlBSICarbapenem29.17 (1.76--484.70)Falagas \[[@CR63]\]2007Retrospective case controlKPC infectionFluoroquinolones\
Antipseudomonal antibiotics4.54 (1.18--11.54)\
2.6 (1.00--6.71)Schwaber \[[@CR61]\]2008Retrospective case--case--controlCRKp colonizationAntibiotics\
Fluoroquinolones4.4 (1--19.2)\
7.2 (1.1--49.4)Gasink \[[@CR60]\]2009Retrospective case--controlKPC infection/colonizationFluoroquinolones\
Third-generation cephalosporin3.39 (1.5--7.66)\
2.55 (1.18--5.22)Papadimitriou \[[@CR64]\]2012Prospective cohortCRKp colonizationBL/BLI\
Carbapenems6.7 (1--26.2)\
5.2 (1--32.9)Tuon \[[@CR90]\]2012Retrospective case--controlKPC bacteremiaFluoroquinolones28.9 (1.85--454.6)Papadimitriou \[[@CR91]\]2014Prospective cohortKPC bacteremiaAminoglycosides2.3 (1.1--4.7)Gagliotti \[[@CR79]\]2014Case--controlKPC colonizationCarbapenems\
Any antibiotic (other than carbapenems)3.67 (1.37--9.83)\
2.83 (1.10--7.31)Maseda \[[@CR92]\]2016RetrospectiveCPE isolate colonizationThird--fourth-generation cephalosporins\
BL/BLI27.96 (6.88--113.58)\
11.71 (4.51--30.43)*KPC Klebsiella pneumoniae*-producing carbapenemase, *CRKp* carbapenem-resistant *Klebsiella pneumoniae*, *BL/BLI* beta-lactams associated with beta-lactamase inhibitors, *BSI* bloodstream infection

Whether carbapenem is the only antibiotic class associated with the selection of carbapenem-resistant gram-negative isolates is an important issue, especially regarding the worldwide spread of carbapenemase-producing Enterobacteriaceae (CPE). These data suggest that antibiotics that disturb the intestinal anaerobic microflora and lack significant activity against KPC-Kp may promote colonization by this organism \[[@CR65]\] (Table [3](#Tab3){ref-type="table"}).Table 3(Adapted from \[[@CR14], [@CR15]\]) usual breakpoints and susceptibility of ESBL-producing EnterobacteriaceaeSusceptibility (%)Breakpoints (mg/L)Ecological impactCommentsThird-generation cephalosporins*Escherichia coli*: \< 10%\
*Klebsiella* species: 3%EUCAST: S ≤ 1\
CLSI: S ≤ 1+++Only for targeted therapy or de-escalation\
MIC requiredCefepime*E. coli*: 5--30%\
*K. pneumoniae*: 5--60%EUCAST: S \< 1\
CLSI: S ≤ 2+++Frequent failure if MICs \> 1 mg/L\
MIC requiredCefoxitin*E. coli*: 80%EUCAST: NA++PK optimizationCeftolozane--tazobactam*E. coli*: 85--95%\
*K. pneumoniae*: 40--65%EUCAST: S ≤ 1\
CLSI: S ≤ 8?Ceftazidime--avibactam*E. coli*: 98--100%\
*K. pneumoniae:* 90--100%EUCAST: S ≤ 8\
CLSI: S ≤ 8?Probably as effective as carbapenemsTemocillin*E. coli* 61% (CMI ≤ 8)\
*E. coli* 99% (CMI ≤ 32)EUCAST: S ≤ 8\
EUCAST: S ≤ 32 (urinary)\
CLSI: S ≤ 8\
CLSI: S ≤ 32 (urinary)±PK optimization (high dosage and prolonged infusion)*CLSI* Clinical and Laboratory Standard Institute, *EUCAST* European Committee on Antimicrobial Susceptibility Testing, *MIC* minimum inhibitory concentration, *NA* not applicable, *PK* pharmacokinetic, *VAP* ventilator-associated pneumonia

Discussion and conclusion {#Sec10}
=========================

In our review of BL/BLI for the treatment of ESBL-PE, we found that they may be an alternative to carbapenems in a selected number of cases, based on antibiogram and CMI data, and always with pk/pd optimization.

The use of alternatives for empirical therapy in suspected ESBL-related infections is usually limited by the level of resistance \[[@CR66]\], the risk of selecting resistant mutants \[[@CR6]\] and clinical effectiveness \[[@CR19]\]. We focused on BL/BLIs, chiefly piperacillin--tazobactam. Indeed, based on epidemiological data, the use of third- or fourth-generation cephalosporins such as cefepime is limited because of a high proportion of resistant isolates \[[@CR66]\] that varies between 10 and 50% and concerns on their clinical efficacy with the associated risks of adverse patient outcomes \[[@CR54]\]. The use of other alternatives such as temocillin is limited by unfavorable PK/PD parameters in critically ill patients \[[@CR49]\].

The efficacy of Pip/Taz antibiotics on ESBL-PE depends on the variety and amount of enzyme produced by the isolates (Table [4](#Tab4){ref-type="table"}). Overall, the rate of susceptibility of ESBL-PE to Pip/Taz is around 80% \[[@CR28]\]. It may be reduced when the organisms produce multiple ESBLs, particularly if they also harbor an AmpC beta-lactamase \[[@CR67]\]. Also it will vary within and between beta-lactamases classes \[[@CR68]\]. The presence of additional resistance mechanisms may further decrease the activity of Pip/Taz against ESBL-producing organisms.Table 4(Adapted from Bonomo and Van Duin) Activity in clinical practice of different beta-lactamase inhibitors, according to type of enzymes \[[@CR68], [@CR111]\]EnzymesClassSubstratesClavulanic acidSulbactamTazobactamAvibactamTEM-1, TEM-2, SHV-1APenicillins, early cephalosporins+--++TEM-3, SHV-2 CTX-M-14AExtended-spectrum cephalosporins, monobactams----++KPC-2, KPC-3ABroad spectrum including carbapenems------+IMP-1, NDM-1, VIM-1BBroad spectrum including carbapenems, but not monobactams--------Escherichia coli AmpCCCephalosporins----±+OXA-48DCarbapenem------+

In the absence of a well-designed prospective randomized study comparing carbapenems to non-carbapenems in ICU patients infected with ESBL-PE, we must rely on the evidence provided by observational data. Observational studies considering the empirical treatment of ESBL-related infections with BL/BLIs have infrequently included ICU patients \[[@CR12]\] and more often involved urinary or biliary tract infection caused by *E. coli* species \[[@CR51]\]. Although several studies suggested no difference in mortality \[[@CR12], [@CR51], [@CR69]\], 2 publications raise the warning of a potential negative impact of BL/BLI when used in patients with ESBL-PE \[[@CR19], [@CR20]\].

Furthermore, when analyzing those publications with a focus on the use of alternatives to carbapenems for definitive therapy, a number of limitations hamper the interpretation of studies comparing BL/BLI to carbapenems.

Firstly most of these studies were not designed to compare different antibiotic strategies. Secondly, the authors did not take into account the severity of underlying diseases, delays to antimicrobial treatment and effectiveness source control, which are all major predictors of outcome \[[@CR70]\]. Thirdly, patients included differed largely across studies, with regard to sources of bacteremia, species involved and type of beta-lactamases; moreover, various antibiotics and different daily doses administered were included in the "alternative" group.

Fourthly, most of the studies included infections related to ESBL-producing *Escherichia coli* and did not account for the impact of MICs and pharmacodynamics data. The impact of MIC seems to be crucial for therapeutic efficacy when using alternatives to carbapenems as the cornerstone of treatment. Several studies \[[@CR12]\] emphasize the risk of treatment failure when using a BL/BLI or third-generation cephalosporin for therapy of infection with isolates having MICs higher than the breakpoints. Indeed, as suggested by a recent pharmacological study, the efficacy of BL/BLI in the treatment of ESBL-related infections is related to the concentration reached in the plasma and at the site of infection \[[@CR71]\]. However, as demonstrated by several authors \[[@CR72]\] the probability of attaining therapeutic drug levels in ICU patients is low and variable depending on the antibiotic considered and dosing strategies \[[@CR35]\]. Also it seems important to have MIC for piperacillin--tazobactam before using this class of antibiotic. Considering several problems related to piperacillin--tazobactam gradient tests and differences noted between gradient tests and broth microdilution, it is recommended now to use broth microdilution.

There are now enough published data on the pk/pd of piperacillin/tazobactam to recommend the use of high daily doses and prolonged infusion ICU patients and in all cases of difficult to treat pathogens such as ESBL-PE.

The ecological consequences of a given antibiotic class depend on the amount of drug reaching the different microbiota. The net result depends on both the antibiotic concentrations achieved and the susceptibility of bacterial species in the microbiota. All antibiotics alter the composition, diversity and density of the microbiota and select for antibiotic resistance \[[@CR73]\]. The "ecological consequences," however, may differ according to the antibiotic used. Increasing consumption of carbapenems raises concerns on the spread of carbapenem-resistant Enterobacteriaceae and specifically carbapenemase-producing Enterobacteriaceae (CPE) \[[@CR74]\]. Also, there are some discrepancies between the first published studies \[[@CR75], [@CR76]\] and the more recent ones \[[@CR6]\] regarding the ecological effect of carbapenems. There is a significant correlation between carbapenem consumption and rates of *Pseudomona*s *aeruginosa* resistance to imipenem and meropenem \[[@CR6], [@CR53]\]. However, this mechanism of resistance is not due to the effect of antibiotics on the microbiota, but the consequence of chromosomal mutation. Earlier human studies \[[@CR77]\] and animal models \[[@CR78]\] suggested a limited impact on the microbiota of this class of antibiotics. However, whatever the antibiotic used, selective antibiotic pressure is an important determinant of emergence and dissemination of antibiotic resistance \[[@CR61], [@CR62]\], and the increasing use of carbapenems will necessarily be associated with the increase in multidrug-resistant organisms \[[@CR65]\]. Our review underlines the fact that the administration of several other antibiotics can also be associated with the emergence of carbapenem-resistant organisms \[[@CR60]--[@CR64], [@CR79]--[@CR92]\]. Nevertheless, the heterogeneity of studies makes their comparison difficult. Indeed, all these studies are subject to several limitations, including inadequate adjustment for important confounding variables, control group selection, extent of prior antibiotic exposure and measurements of resistance outcomes.

One of the limitations of our study lies in the fact that we did not mentioned the two recent BL/BLIs approved by FDA and EMA, ceftolozane--tazobactam and ceftazidime--avibactam which are active in vitro against ESBL-producing Enterobacteriaceae. Several recent studies highlighted the in vitro efficacy of these two antibiotics on ESBL-producing Enterobacteriaceae \[[@CR67], [@CR93]\]. Also clinical data are scarce. Indeed for nosocomial pneumonia, a phase III study (MK-7625A-008) is currently leaded using ceftolozane--tazobactam.

A definitive answer to the question addressed in this review would need a randomized study conducted in ICU, including severe infections related to ESBL-PE. Cases should be selected according to the results of antibiotic susceptibility tests, and the trial should compare carbapenems to BL/BLI as definitive therapy. Pending such a trial, piperacillin--tazobactam should be used with caution for treatment of ESBL-PE-related infections. In ICU patients, empirical use should be avoided, and definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests, together with adapting the administered dose and modalities of infusion to the MIC of the infecting microorganism in order to reach pharmacological targets.
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TDM

:   therapeutic drug monitoring

TID

:   three times in a day

BP contributed to conception and design of the study, responsible for the "clinical studies" portion and gave final approval of the version to be published. VJ contributed to conception and design of the study, responsible for the "pharmacokinetics and pharmacodynamic studies" portion and gave final approval of the version to be published. AT revised the manuscript critically for important intellectual content and gave final approval of the version to be published. JRZ contributed to conception and design of the study, responsible for the "ecological studies" portion and gave final approval of the version to be published. CBB involved in design of the study, revised it critically for important intellectual content and gave final approval of the version to be published.

Acknowledgements {#FPar1}
================

Not applicable.

Competing interests {#FPar2}
===================

BP, AT and CBB declare that they have no competing interests. VJ has received research grants from Astellas, Sanofi-Aventis, Biocodex and travel Grants from MSD. JRZ has participated in an advisory board for MSD.

Availability of data and materials {#FPar3}
==================================

Details regarding the literature search strategy and the terms used are provided in online supplement. We fully agree to discuss and share key data with interested individuals.

Consent for publication {#FPar4}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar5}
==========================================

Not applicable.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
